Nicholas Hall's Three More Years of M&ANicholas Hall and CompanyMarch 1, 2011 255 Pages - SKU: NHC6482004 |
- Overview
- OTC Market & Trends
- The OTC market and trends
- OTC market by region
- Strategy options for OTC players
- Organic growth vs acquisition
- Industry Consolidation
- The search for critical mass
- The impact of Big Pharma on OTC
- The pace hots up since 2000
- M&A Review of 2010-11
- P&G / Teva OTC tie-up
- M&A Strategy
- M&A strategy of the global Top 20
- Johnson & Johnson
- GlaxoSmithKline
- Bayer
- Novartis
- Pfizer
- Sanofi-Aventis
- Reckitt Benckiser
- Taisho
- Boehringer Ingelheim
- Procter & Gamble
- MSD
- Kraft
- Otsuka
- Takeda
- Bristol-Myers Squibb
- NBTY
- Teva
- Hypermarcas
- Daiichi Sankyo
- Nycomed
- Cashing out & Buying in
- Leading International Targets
- Abbott
- AstraZeneca
- Boiron
- CB Fleet
- Church & Dwight
- Mundi Group
- Pohl Boskamp
- Schwabe
- Leading North American Targets
- Afexa Life Sciences
- Airborne
- Alacer
- Bausch & Lomb
- Blistex
- Insight Pharmaceuticals
- Jamieson
- Prestige Brands
- Leading European Targets
- Actavis
- Alfa Wasserman
- Almirall Prodesfarma
- Angelini
- Arkopharma
- Beiersdorf
- Biocodex
- Biogaran
- Bionorica
- Cephalon
- Chiesi
- Cooper
- Engelhard
- Esteve
- Expanscience
- Galenica
- Gedeon Richter
- IBSA
- Jadran Galenski
- Krka
- Meda
- Menarini
- Merz
- Norgine
- Omega Pharma
- Orthomol
- Pharmstandart
- Pierre Fabre
- Polpharma
- Queisser
- Rottapharm | Madaus
- Stada
- UCB
- USP
- Zambon
- Leading Asia-Pacific Targets
- 999 Pharmaceutical
- Arax
- Beijing Four Rings
- Blackmores
- Dabur
- Daewoong
- Dong-A
- Dong Wha
- Emami Group
- Fushan DeZhong Pharma
- Guangxi Golden Throat
- Guangzhou Pan Gao Shou
- Guilin Sanjin
- Guizhou ShenQi
- Hayao Group
- Ikeda Mohando
- iNova
- Kalbe Farma
- Konimex
- Lion
- Livzon
- Nin Jiom
- Piramal
- Tempo
- United Laboratories
- Yunnan Baiyao
- Zeria
- Leading Latin American Targets
- Aché
- Andrómaco
- Bagó
- Elea
- EMS
- Genomma Lab
- Grupo Farma
- Lafrancol
- Liomont
- Sanfer
- Tecnoquímicas
- Leading Rest of World Targets
- Abdi Ibrahim
- Adcock Ingram
- Adeka
- Aspen Pharmacare
- Basel
- Bilim
- Dexcel
- Neopharm
- Nutrilida
- Santa Farma
- Spimaco
- The 3 “M”s of M&A: Methodology, Multiples, Magic
- Future Prospects for the OTC Industry
- The OTC market in 2015, 2020
- Winners & Losers
- Does M&A work for OTC?
- M&A winners & losers
- Appendix: M&A Register 2001-11
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Over-the-Counter Drugs Reports